skip to main content
Washington State Institute for Public Policy
Back Button

Primary care in behavioral health settings (community-based settings)

Adult Mental Health: Serious Mental Illness
Benefit-cost methods last updated December 2024.  Literature review updated May 2014.
This program was archived December 2024.
Behavioral health settings (mental health and substance abuse treatment centers) provide primary care for patients on site or nearby. This collection of studies evaluate this practice at community-based treatment centers.
 
ALL
BENEFIT-COST
META-ANALYSIS
CITATIONS
For an overview of WSIPP's Benefit-Cost Model, please see this guide. The estimates shown are present value, life cycle benefits and costs. All dollars are expressed in the base year chosen for this analysis (2022).  The chance the benefits exceed the costs are derived from a Monte Carlo risk analysis. The details on this, as well as the economic discount rates and other relevant parameters are described in our 2023 Technical Documentation.
Benefit-Cost Summary Statistics Per Participant
Benefits to:
Taxpayers ($27) Benefits minus costs ($610)
Participants ($185) Benefit to cost ratio ($0.89)
Others $64 Chance the program will produce
Indirect ($139) benefits greater than the costs 27%
Total benefits ($288)
Net program cost ($322)
Benefits minus cost ($610)

^WSIPP’s benefit-cost model does not monetize this outcome.

Meta-analysis is a statistical method to combine the results from separate studies on a program, policy, or topic to estimate its effect on an outcome. WSIPP systematically evaluates all credible evaluations we can locate on each topic. The outcomes measured are the program impacts measured in the research literature (for example, impacts on crime or educational attainment). Treatment N represents the total number of individuals or units in the treatment group across the included studies.

An effect size (ES) is a standard metric that summarizes the degree to which a program or policy affects a measured outcome. If the effect size is positive, the outcome increases. If the effect size is negative, the outcome decreases. See Estimating Program Effects Using Effect Sizes for additional information on how we estimate effect sizes.

The effect size may be adjusted from the unadjusted effect size estimated in the meta-analysis. Historically, WSIPP adjusted effect sizes to some programs based on the methodological characteristics of the study. For programs reviewed in 2024 or later, we do not make additional adjustments, and we use the unadjusted effect size whenever we run a benefit-cost analysis.

Research shows the magnitude of effects may change over time. For those effect sizes, we estimate outcome-based adjustments, which we apply between the first time ES is estimated and the second time ES is estimated. More details about these adjustments can be found in our 2023 Technical Documentation.

Meta-Analysis of Program Effects
Outcomes measured Treatment age No. of effect sizes Treatment N Effect sizes (ES) and standard errors (SE) used in the benefit-cost analysis Unadjusted effect size (random effects model)
First time ES is estimated Second time ES is estimated
ES SE Age ES SE Age ES p-value
Regular smoking
Smoking tobacco on a regular basis.
 41 1 453 0.116 0.194 41 0.000 0.000 42 0.116 0.548
Obesity
Obese based on clinical guidelines for adults (body mass index of 30 or higher) or children (body mass index at or above the 95th percentile for children of the same age and sex), as appropriate.
41 1 435 -0.002 0.194 41 n/a n/a n/a -0.002 0.992
Hospitalization
Hospital admission, for any reason.
 41 4 852 -0.052 0.092 41 0.000 0.000 42 -0.052 0.572
Emergency department visits
Whether someone visited the emergency department, or the number of times they visited the emergency department.
41 6 6585 -0.081 0.051 41 0.000 0.000 42 -0.081 0.117
Blood pressure^
Blood pressure in the typical clinical range.
 41 1 441 -0.022 0.194 41 n/a n/a n/a -0.022 0.909
Blood sugar (HbA1c)^
Measure of average blood sugar over 10-12 weeks.
 41 1 321 -0.015 0.198 41 n/a n/a n/a -0.015 0.940
Cholesterol^
Total cholesterol (low-density lipoprotein and high-density lipoprotein).
 41 1 370 -0.188 0.196 41 n/a n/a n/a -0.188 0.338
Primary care visits^
Visit to a primary care physician for any reason.
 41 5 944 0.111 0.197 41 n/a n/a n/a 0.111 0.020
1In addition to the outcomes measured in the meta-analysis table, WSIPP measures benefits and costs estimated from other outcomes associated with those reported in the evaluation literature. For example, empirical research demonstrates that high school graduation leads to reduced crime. These associated measures provide a more complete picture of the detailed costs and benefits of the program.

2“Others” includes benefits to people other than taxpayers and participants. Depending on the program, it could include reductions in crime victimization, the economic benefits from a more educated workforce, and the benefits from employer-paid health insurance.

3“Indirect benefits” includes estimates of the net changes in the value of a statistical life and net changes in the deadweight costs of taxation.
Detailed Monetary Benefit Estimates Per Participant
Affected outcome: Resulting benefits:1 Benefits accrue to:
Taxpayers Participants Others2 Indirect3 Total
Regular smoking Labor market earnings associated with smoking ($81) ($191) $0 $0 ($271)
Health care associated with smoking ($18) ($5) ($19) ($9) ($51)
Mortality associated with smoking $0 $0 $0 ($5) ($5)
Hospitalization Health care associated with general hospitalization $46 $2 $46 $23 $117
Emergency department visits Health care associated with emergency department visits $25 $7 $37 $12 $81
Obesity Labor market earnings associated with obesity $1 $2 $0 $0 $3
Mortality associated with obesity $0 $0 $0 $0 $0
Program cost Adjustment for deadweight cost of program $0 $0 $0 ($161) ($161)
Totals ($27) ($185) $64 ($139) ($288)
Click here to see populations selected
Detailed Annual Cost Estimates Per Participant
Annual cost Year dollars Summary
Program costs $270 2014 Present value of net program costs (in 2022 dollars) ($322)
Comparison costs $0 2014 Cost range (+ or -) 20%
According to Samet et al. (2003). Linking alcohol- and drug-dependent adults to primary medical care: A randomized controlled trial of a multi-disciplinary health intervention in a detoxification unit. Addiction, 98(4), 509-516, patients in the treatment group received an average of 1 more primary care visit in 12 months than did those in the comparison group. The average visit cost for primary care visit at Navos in Seattle (an example of a community-based treatment center) is $270 (per email from Paul Tagenfeldt to M. Miller, April 25, 2014).
The figures shown are estimates of the costs to implement programs in Washington. The comparison group costs reflect either no treatment or treatment as usual, depending on how effect sizes were calculated in the meta-analysis. The cost range reported above reflects potential variation or uncertainty in the cost estimate; more detail can be found in our 2023 Technical Documentation.
Benefits Minus Costs
Benefits by Perspective
Taxpayer Benefits by Source of Value
Benefits Minus Costs Over Time (Cumulative Discounted Dollars)
The graph above illustrates the estimated cumulative net benefits per-participant for the first fifty years beyond the initial investment in the program. We present these cash flows in discounted dollars. If the dollars are negative (bars below $0 line), the cumulative benefits do not outweigh the cost of the program up to that point in time. The program breaks even when the dollars reach $0. At this point, the total benefits to participants, taxpayers, and others, are equal to the cost of the program. If the dollars are above $0, the benefits of the program exceed the initial investment.

Citations Used in the Meta-Analysis

Friedmann, P.D., Hendrickson, J.C., Gerstein, D.R., Zhang, Z., & Stein, M.D. (2006). Do Mechanisms That Link Addiction Treatment Patients to Primary Care Influence Subsequent Utilization of Emergency and Hospital Care?. Medical Care, 44(1), 8-15.

Laine, C., Hauck, W.W., & Turner, B.J. (2005). Availability of Medical Care Services in Drug Treatment Clinics Associated with Lower Repeated Emergency Department Use. Medical Care, 43(10), 985-995.

Scharf, D.M, Eberhart, N.K., Horvitz-Lennon, M., R. Beckman, Han, B., Lovejoy, S., Pincus, H.A., Burnam, M.A. (2013). Evaluation of the SAMHSA Primary and Behavioral ehalth Care Integration Program: Final report. Rand Corporation. http://aspe.hhs.gov/daltcp/reports/2013/PBHCIfr.shtml

Umbricht-Schneiter, A., Ginn, D.H., Pabst, K.M., & Bigelow, G.E. (1994). Providing medical care to methadone clinic patients: referral vs on-site care. American Journal of Public Health, 84(2), 207-210.